Thermo Fisher Scientific has launched two next-generation sequencing-based assays aimed at accelerating research in fertility and reproductive health. These tools are designed to work with the Ion Torrent Genexus Integrated Sequencer and are intended for research use only meaning they are not meant to be used in diagnostic procedures.
Based in Carlsbad, California, Thermo Fisher Scientific has introduced the Ion ReproSeq PGT-A Kit and the Ion AmpliSeq Polyploidy Kit. These two new assays are compatible with the Ion Torrent Genexus Integrated Sequencer, providing an all-in-one solution for aneuploidy analysis in fertility research. This compatibility also means that more research labs will be able to undertake comprehensive PGT-A analysis.
The use of assisted reproductive technology like IVF has more than doubled in the past decade and aneuploidy testing, which identifies chromosomal abnormalities in embryos, is increasingly used in fertility research to improve outcomes. The ReproSeq PGT-A Kit enables researchers to gather genetic insights that may improve the success rate of future pregnancies. The Ion AmpliSeq Polyploidy Kit provides additional quality control measures, including the detection of contamination and the ability to identify triploidy in embryos.
“Building on Thermo Fisher’s existing reproductive health offerings, this launch brings the benefits of next-generation sequencing to more research labs with the potential of rapid, in-house testing and analysis,” said Garret Hampton, president, clinical next-generation sequencing and oncology at Thermo Fisher Scientific. “Considering the far-reaching implications for those struggling with infertility, researchers must have reliable and accurate testing available to advance the fertility field and ultimately improve reproductive health for all. We’re committed to delivering comprehensive, complete solutions that can make this type of exploration a reality.”
